{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:05Z","timestamp":1792293545563,"version":"4.4.0"},"reference-count":35,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) with [Lutetium-177-DOTA0-Tyr3]octreotate (177Lu-DOTATATE) results in an increase of progression-free survival and quality of life in patients with progressive, well-differentiated neuroendocrine neoplasms (NENs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To study the effect of 177Lu-DOTATATE in patients with carcinoid syndrome and radiologically stable or newly diagnosed disease treated solely for the purpose of symptom reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Tertiary care hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Twenty-two patients with a metastatic midgut NEN, elevated urinary 5-hydroxyindolacetic acid excretion, and flushing and\/or diarrhea despite treatment with a somatostatin analog, without documented disease progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>PRRT with 177Lu-DOTATATE (intended cumulative dose: 29.6 GBq) with a primary aim to reduce symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After PRRT, mean bowel movement frequency (BMF) decreased from 6.1 \u00b1 3.4 to 4.6 \u00b1 3.6 per day (P = 0.009). Flushes decreased from 4.3 \u00b1 2.9 to 2.4 \u00b1 2.7 flushes per day (P = 0.002). A decrease of BMF of more than 30% occurred in 47% of patients with baseline BMF of 4 or more (n = 17). In patients with \u22652 episodes of flushing a day (n = 15), 67% of patients had more than 50% decrease of daily flushing. A decrease in urinary 5-hydroxyindolacetic acid excretion of more than 30% was seen in 56% of patients. The European Organization for Research and Treatment of Cancer\u2013Core Module diarrhea subscale score showed a trend toward improvement by an average of 16.7 \u00b1 33.3 points (P = 0.11).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PRRT with 177Lu-DOTATATE effectively reduced diarrhea and flushing in patients with carcinoid syndrome and can be considered for symptomatic treatment of carcinoid syndrome insufficiently controlled with somatostatin analogs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab289","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T03:16:31Z","timestamp":1620098191000},"page":"e3665-e3672","source":"Crossref","is-referenced-by-count":54,"title":["Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7979-6969","authenticated-orcid":false,"given":"Wouter T","family":"Zandee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Sector Endocrinology, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"},{"name":"University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Division of Endocrinology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-6490","authenticated-orcid":false,"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anela","family":"Bla\u017eevi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector Endocrinology, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie S","family":"Minczeles","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector Endocrinology, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"},{"name":"Department of Radiology & Nuclear Medicine, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-391X","authenticated-orcid":false,"given":"Richard A","family":"Feelders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector Endocrinology, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-5165","authenticated-orcid":false,"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector Endocrinology, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-6209","authenticated-orcid":false,"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sector Endocrinology, ENETS Center of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"1","key":"2021120108545061500_CIT0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2017.05.034","article-title":"Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways","volume":"170","author":"Bellono","year":"2017","journal-title":"Cell."},{"issue":"4306","key":"2021120108545061500_CIT0002","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/169800b0","article-title":"Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine","volume":"169","author":"Erspamer","year":"1952","journal-title":"Nature."},{"issue":"3","key":"2021120108545061500_CIT0003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1530\/ERC-17-0282","article-title":"Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours","volume":"25","author":"Bla\u017eevi\u0107","year":"2018","journal-title":"Endocr Relat Cancer."},{"issue":"2","key":"2021120108545061500_CIT0004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/gut.11.2.189","article-title":"Progress report: the carcinoid syndrome","volume":"11","author":"Grahame-Smith","year":"1970","journal-title":"Gut."},{"issue":"2","key":"2021120108545061500_CIT0005","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev."},{"issue":"4","key":"2021120108545061500_CIT0006","doi-asserted-by":"crossref","first-page":"525-534","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"2021120108545061500_CIT0007","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/ERC-16-0538","article-title":"Effect of hormone secretory syndromes on neuroendocrine tumor prognosis","volume":"24","author":"Zandee","year":"2017","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"2021120108545061500_CIT0008","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas."},{"issue":"3","key":"2021120108545061500_CIT0009","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/ERC-18-0495","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","volume":"26","author":"Hofland","year":"2019","journal-title":"Endocr Relat Cancer."},{"issue":"28","key":"2021120108545061500_CIT0010","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021120108545061500_CIT0011","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla","year":"2012","journal-title":"J Endocrinol Invest."},{"key":"2021120108545061500_CIT0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000201403","article-title":"Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours","volume":"57 Suppl 1","author":"Oberg","year":"1996","journal-title":"Digestion."},{"key":"2021120108545061500_CIT0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2141.1991.tb08125.x","article-title":"The role of interferons in the management of carcinoid tumours","volume":"79 Suppl 1","author":"Oberg","year":"1991","journal-title":"Br J Haematol."},{"issue":"1","key":"2021120108545061500_CIT0014","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021120108545061500_CIT0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med."},{"issue":"25","key":"2021120108545061500_CIT0016","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol."},{"issue":"9","key":"2021120108545061500_CIT0017","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med."},{"issue":"4","key":"2021120108545061500_CIT0018","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021120108545061500_CIT0019","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-16-0392","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours","volume":"175","author":"Zandee","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"16","key":"2021120108545061500_CIT0020","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2021120108545061500_CIT0021","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med."},{"issue":"12","key":"2021120108545061500_CIT0022","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021120108545061500_CIT0023","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"2021120108545061500_CIT0024","volume-title":"EORTC QLQ-C30 Scoring Manual.","author":"Fayers","year":"2001"},{"issue":"2","key":"2021120108545061500_CIT0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"2","key":"2021120108545061500_CIT0026","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00259-013-2578-5","article-title":"Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy","volume":"41","author":"Seregni","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2021120108545061500_CIT0027","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med."},{"issue":"6","key":"2021120108545061500_CIT0028","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-Octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med."},{"issue":"3","key":"2021120108545061500_CIT0029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer."},{"issue":"7","key":"2021120108545061500_CIT0030","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1989.7.7.865","article-title":"Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon","volume":"7","author":"Moertel","year":"1989","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021120108545061500_CIT0031","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/02841868909111220","article-title":"Interferon treatment in patients with malignant carcinoids","volume":"28","author":"Nobin","year":"1989","journal-title":"Acta Oncol."},{"issue":"1","key":"2021120108545061500_CIT0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0959-8049(92)90389-J","article-title":"A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour","volume":"28","author":"Veenhof","year":"1992","journal-title":"Eur J Cancer."},{"issue":"2","key":"2021120108545061500_CIT0033","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/02841869309083918","article-title":"Treatment of carcinoid syndrome with recombinant interferon alpha-2a","volume":"32","author":"Di Bartolomeo","year":"1993","journal-title":"Acta Oncol."},{"issue":"8","key":"2021120108545061500_CIT0034","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2021120108545061500_CIT0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab289\/38392941\/dgab289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/e3665\/41378883\/dgab289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/e3665\/41378883\/dgab289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:46:47Z","timestamp":1638366407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/9\/e3665\/6263447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5,4]]},"published-print":{"date-parts":[[2021,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab289","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,5,4]]}}}